connecticut medicaid glp-1 weight loss coverage 2025 People call GLP-1s life-changing. CT says it can't afford them Medicaid Coverage of and Spending

In research settings it is investigated as a stable peptide that may interact with tissue-repair and vascular signaling pathways

5 Two factors drive this gap: Early discontinuation: About 22 % of semaglutide users and 16% of tirzepatide users stopped treatment within the first year, and many more quit after the one-year mark

SERT Ala56 mice that expressed an ASD-associated variant in humans exhibited elevations of 5-HT clearance in the brain and ASD-related social impairments and repetitive behavior, but forebrain 5-HT levels did not change in the mutants (149)

And on one hand, people are eating less and they are dropping weight

FAQs Safety Questions Users Ask Most Still unsure about the safety of BPC-157